Treatment
Glucagon clinical trials
We’re tracking 37 recruiting studies that include Glucagon, each written for real people, not researchers, below.
Recruiting studies
- NCT06498063Recruiting
Glucagon and kidney effects in healthy males
This trial tests how the hormone glucagon affects kidney function in healthy men. It may help researchers understand how glucagon works in the body.
CopenhagenAges 20–60 - NCT07613307RecruitingPhase 3
Study of a new pill for type 2 diabetes during Ramadan fasting
This study tests an oral medication called orforglipron to see if it safely helps people with type 2 diabetes manage their blood sugar while they fast during Ramadan. You may be a good fit if you are planning to fast and your diabetes is not too severe.
AgraAges 18–65 - NCT07212868RecruitingPhase 1
How glucagon affects blood sugar after weight loss surgery
This study looks at how the hormone glucagon affects blood sugar in people who have had gastric bypass or sleeve gastrectomy surgery more than a year ago, compared to people who have not had any gastrointestinal surgery. It aims to understand glucose metabolism better and may help improve care for people after bariatric surgery.
San Antonio, TexasAges 18–65 - NCT07319286Enrolling by invitationPhase 1/Phase 2
GLP-1 drug for period problems in teens with type 1 diabetes
This trial tests whether a GLP-1 receptor agonist can help improve irregular periods in teenage girls with type 1 diabetes. It's for girls aged 12 to 18 who have had their period for at least 2 years, use a continuous glucose monitor, and have higher blood sugar levels (HbA1c of 7% or more).
Cairo, Cairo GovernorateAges 12–18 - NCT07702461Recruiting
Resistance training survey for people on weight loss meds
This trial is an online survey to understand how people taking GLP-1 medications (like Ozempic or Wegovy) are doing with resistance training. If you're an adult on a stable dose of a GLP-1 med for weight or diabetes, your input can help shape better exercise advice.
Columbus, OhioAges 18 years+ - NCT06424106Recruiting
Glucagon & fasting insulin in people without type 2 diabetes
This study looks at how glucagon affects insulin release and blood sugar in people who do not have type 2 diabetes. It may help us understand normal glucose control better.
Rochester, MinnesotaAges 25–65 - NCT06770621Recruiting
Glucagon response study in new type 1 diabetes
This study looks at how the body makes glucagon (a hormone that raises blood sugar) in children and teens with new type 1 diabetes. It aims to understand why some people may have dangerous low blood sugars, so doctors can better prevent them in the future.
Brussels, Woluwe-saint-lambertAges 2–30 - NCT07140289Enrolling by invitation
GLP-1 drugs and stomach emptying before surgery
This study looks at how GLP-1 medications affect the time it takes for your stomach to empty before anesthesia. It may help doctors decide if you need to take special precautions before your surgery.
Detroit, MichiganAges 18–90 - NCT06581120Enrolling by invitation
Stomach ultrasound study for diabetes and obesity
This study uses ultrasound to see how GLP-1 RA medications (like Ozempic) affect the stomach in people with type 2 diabetes and obesity. It may help doctors better understand how these medicines work.
Cincinnati, OhioAges 10–25 - NCT07575399RecruitingPhase 3
Switching to a New Weight-Loss Medication From Current GLP-1
This trial tests whether switching from your current GLP-1 medication (like Ozempic or Wegovy) to a new drug called maridebart cafraglutide works as well or better for weight management. You must have already lost at least 10% of your body weight on your current GLP-1 and be doing well with it.
Pelham, AlabamaAges 18–99 - NCT07427251RecruitingPhase 4
Study to avoid low blood sugar after meals
This trial tests if a quick-acting glucagon nasal spray can prevent low blood sugar after meals in people with type 1 diabetes who use an automated insulin pump. If you count carbs and use NovoRapid or Fiasp insulin, this could help you avoid post-meal lows.
HerlevAges 18 years+ - NCT07111494RecruitingPhase 4
GLP-1 medication for psoriatic arthritis outcomes
This study tests if adding a GLP-1 medication (a type of drug that helps with weight and blood sugar) to your usual psoriatic arthritis treatment can improve your joint and skin symptoms. It is for people with psoriatic arthritis who have not yet achieved good control of their disease and have a higher body weight.
Milwaukee, WisconsinAges 18 years+ - NCT06647368Recruiting
Measuring brain sugar use with glucagon
This study tests a new way to measure how the brain uses sugar (glucose) to see if the hormone glucagon affects it. It may help researchers understand how certain hormones work in the body.
CopenhagenAges 25–70 - NCT06654219Recruiting
Clear liquids before endoscopy for patients on GLP-1 meds
This study tests whether drinking only clear liquids before an upper endoscopy can reduce leftover stomach contents in people taking GLP-1 medications (like Ozempic or Mounjaro). It may help make the procedure safer.
Houston, TexasAges 18 years+ - NCT04200391Recruiting
Low-carb diet study and how glucagon affects diabetes
This study tests whether very low-carbohydrate diets change glucagon response in adults with type 1 diabetes. It may help researchers understand how diet affects blood-sugar control in people using insulin pumps and continuous glucose monitors.
Boston, MassachusettsAges 18–40 - NCT05499702RecruitingPhase 2
Glucagon test after dieting in type 2 diabetes
This Phase 2 study tests how glucagon affects sugar and fat handling in the liver after a short period of calorie restriction. It may help researchers understand metabolic changes in people with type 2 diabetes and guide future treatments.
Rochester, MinnesotaAges 25–65 - NCT05663515Recruiting
Checks pancreatic cancer risk after starting exenatide in type 2 diabetes
This study looks at whether starting exenatide (a type 2 diabetes medicine) is linked to a higher or lower risk of pancreatic cancer compared with other similar diabetes medicines. It uses people’s prescription and medical record history to compare risks over time.
CopenhagenAges 18–99 - NCT05938712RecruitingPhase 2
Kidney transplant trial using two diabetes medicines safely
This Phase 2 trial tests whether combining two diabetes medicines—an SGLT2 tablet and a GLP-1 shot (semaglutide)—can improve kidney outcomes and safety in people with a kidney transplant. It may help some recipients, but it also carefully checks for infection risk, diabetes complications, and pregnancy plans.
Toronto, OntarioAges 18 years+ - NCT06069622Recruiting
How a gene affects weight-loss treatment response
This study looks at how a weight-loss medication affects people with obesity who may have a specific gene difference (caveolin-1). It aims to understand why some people respond differently to GLP-1 treatments like semaglutide.
Boston, MassachusettsAges 18 years+ - NCT06252493Recruiting
PET/MR scan for Crohn's disease scar tissue
This study is testing a new imaging method that uses a special PET/MR scan to see how active Crohn's disease is in your bowel. The scan uses a harmless radioactive tracer that attaches to scar tissue, which may help doctors better understand the disease and guide treatment.
Charlestown, MassachusettsAges 18–99 - NCT07091500Recruiting
Exercise and a weight-loss drug for people with obesity
This trial tests whether combining a GLP-1 medication (a type of diabetes drug that also helps with weight loss) with an exercise program can improve physical function in people with obesity. If you are obese and have trouble with daily activities, this study may help you become more mobile and healthier.
St Louis, MissouriAges 50–75 - NCT06461377RecruitingPhase 4
GLP-1RA for heart nerve damage in type 2 diabetes
This trial tests whether a type of diabetes medicine called GLP-1RA can help prevent or improve nerve damage in the heart caused by diabetes. It is for people with type 2 diabetes who are overweight or obese.
Nanjing, JiangsuAges 18–70 - NCT06582875RecruitingPhase 2
GLP-1 drug for polycystic kidney disease and weight
This study tests a GLP-1 receptor agonist (a type of medicine that helps with weight and metabolism) in people with polycystic kidney disease who are overweight. It aims to see if this drug can help slow kidney disease progression.
Aurora, ColoradoAges 18–65 - NCT06592261RecruitingPhase 1
Insulin suppression test for weight groups
This study tests a new way to measure how the body handles insulin in people with different body weights. It may help researchers understand insulin resistance better.
New York, New YorkAges 18–65
What Glucagon is being studied for
Conditions with recruiting Glucagon studies.
Common questions
- Are there clinical trials studying Glucagon?
- Yes. Clin2 currently lists 37 recruiting studies that include Glucagon, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Glucagon trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Glucagon an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Glucagon or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.